Cite

HARVARD Citation

    Wareham, J. et al. (n.d.). P247 Lumacaftor/ivacaftor is associated with high discontinuation rates in patients with baseline severe lung function but also benefits in those who tolerate therapy. Thorax. p. A218. [Online]. 
  
Back to record